Leaderboards/Myeloproliferative Neoplasms: Diagnosis and Treatment

Myeloproliferative Neoplasms: Diagnosis and Treatment

Last updated June 1, 2026

Rising Stars

New and hot

Rising Stars Researchers

1
Courtney D. DiNardo
The University of Texas MD Anderson Cancer Center
99
2
Gabriela Hobbs
Massachusetts General Hospital
93
3
Andrew Kuykendall
Moffitt Cancer Center
84
4
Hans Carl Hasselbalch
University of Copenhagen
83
5
Giuseppe Rosano
Università degli studi di Cassino e del Lazio Meridionale
82
6
Alberto Martínez
Silence Therapeutics (United Kingdom)
77
7
Chloé James
Université de Bordeaux
77
8
Patrick Harrington
King's College London
74
9
Mandy N. Lauw
Erasmus MC
72
10
Tomasz Wróbel
Wroclaw Medical University
71

Rising Stars Papers

Insufficient data

Emerging Leaders

Gaining momentum

Emerging Leaders Researchers

1
Isabella Diana Davidsen
University of Copenhagen
99
2
Douglas Tremblay
Icahn School of Medicine at Mount Sinai
89
3
Gabriel Antherieu
Hospices Civils de Lyon
89
4
Michelle Nwachukwu
The University of Texas MD Anderson Cancer Center
88
5
Kirti Arora
Cleveland Clinic Akron General
88
6
Rania Abdelaziz
Mayo Clinic
88
7
Yanxia Li
National Marine Sanctuary Foundation
88
8
Yuhan Chen
Englewood Hospital and Medical Center
88
9
Dustin Andersen Patel
University of Copenhagen
88
10
William D. Marrero
The University of Texas MD Anderson Cancer Center
88

Emerging Leaders Papers

Insufficient data

All-Time Leaders

The canon

All-Time Leaders Researchers

1
Ayalew Tefferi
University of Bergamo
99
2
Hagop M. Kantarjian
The University of Texas MD Anderson Cancer Center
99
3
Sahand Hormoz
Broad Institute
93
4
Peter J. Campbell
Wellcome/MRC Cambridge Stem Cell Institute
79
5
Mignon L. Loh
University of California, San Francisco
74
6
Jason Gotlib
Stanford Medicine
68
7
Cindy L. Hochstetler
National Comprehensive Cancer Network
67
8
Veronika Sexl
University of Veterinary Medicine Vienna
66
9
Javier López‐Jiménez
Instituto Cajal
64
10
Therése Andersson
Karolinska Institutet
63

All-Time Leaders Papers

1
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
Leukemia|2016
849 cit.
2
Acute myeloid leukemia: current progress and future directions
Blood Cancer Journal|2021
750 cit.
3
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Blood|2007
744 cit.
4
Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
Blood|2014
722 cit.
5
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
Leukemia|2013
666 cit.
6
The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion
Blood Cancer Journal|2018
632 cit.
7
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Journal of Clinical Oncology|2011
586 cit.
8
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia
Blood|2011
187 cit.
9
Reversible Block of Mouse Neural Stem Cell Differentiation in the Absence of Dicer and MicroRNAs
PLoS ONE|2010
73 cit.
10
A kinase-independent role for CDK8 in BCR-ABL1+ leukemia
Nature Communications|2019
73 cit.

Reagents for Myeloproliferative Neoplasms: Diagnosis and Treatment

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Recommended

Best all-around

Cell Signaling Technology

ATP2A1/SERCA1 (A988) Antibody

Cited in 9 papers
#4274$317
View Evidence →Cell Signaling Technology

Stat5 (D2O6Y) Rabbit Monoclonal Antibody

Cited in 9 papers
#94205$152
View Evidence →Cell Signaling Technology

Bim (C34C5) Rabbit Monoclonal Antibody (Alexa Fluor® 488 Conjugate)

Cited in 8 papers
#94805$465
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Ermin (F4O7S) Rabbit Monoclonal Antibody

Cited in 23 papers
#18962$161
View Evidence →Cell Signaling Technology

PathScan® Phospho-Chk2 (Thr68) Sandwich ELISA Kit

Cited in 11 papers
#7037$661
View Evidence →Cell Signaling Technology

Phospho-Tyrosine Mouse Monoclonal Antibody (P-Tyr-100) (Alexa Fluor® 488 Conjugate)

Cited in 11 papers
#9414$493
View Evidence →